BD BBL Sensi-Disc Ceftazidime - 30 µgRecalls & reported problems across all models

We found 2 models of BD BBL Sensi-Disc Ceftazidime - 30 µg by Becton, Dickinson And Company in the FDA's device registry (GUDID). Together they are named in 1 adverse event report in the FDA's MAUDE database, received between May 9, 2025 and May 9, 2025 — classified as 1 malfunction.

The most frequently reported specific device problem is “Device Markings/Labelling Problem” (1 report).

1 FDA recall record name at least one of these models by its device identifier, 1 still open.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event. Widely used products collect more reports, so totals can't be used to compare products or estimate failure rates. Only reports that name a model's exact device identifier are counted. What reports can and can't tell you · How this data works

BD BBL Sensi-Disc Ceftazidime - 30 µg recalls

FDA recall records that name at least one of these models by its device identifier, newest first. Each recall usually covers specific models or lots, so check the details.

1. Jan 8, 2024Class IIOpen, Classified

   There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.

   Z-1023-2024 · Root cause: Process control · names 2 of these models · Recall details · FDA record ↗

Most reported BD BBL Sensi-Disc Ceftazidime - 30 µg problems

BD BBL Sensi-Disc Ceftazidime - 30 µg models

2 models, most reported first. Each model has its own page with its reports, recalls and device details.

• BD BBL™ Sensi-Disc™ Ceftazidime 30 µg 231633

  SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL
  1 recall1 report
• BD BBL™ Sensi-Disc™ Ceftazidime - 30 µg 231632

  SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL
  1 recall0 reports

Recent BD BBL Sensi-Disc Ceftazidime - 30 µg adverse event reports

The 1 most recent reports across all models, in the reporter's own words as published by the FDA.

• MalfunctionMay 9, 2025Device Markings/Labelling Problem; Device Markings/Labelling Problem

  IT WAS REPORTED PRIOR TO USING THE BD BBL¿ SENSI-DISC¿ CEFTAZIDIME 30 ¿G, THE USER NOTED THAT THE LABEL OF THE CARTRIDGE CONTAINING THE PRODUCT (INTERNAL LABELING) WAS DIFFERENT FROM THE SHELF PACKAGE LABEL (EXTERNAL LABEL). NO HEALTH IMPACT OR CONSEQUENCE REPORTED.

  Patient problems: No Clinical Signs, Symptoms or Conditions

  MAUDE report 21997189 ↗

Other Becton, Dickinson And Company products

• BD Vacutainer SST10 models · 4,985 reports · 3 recalls
• BD Luer-Lok48 models · 5,117 reports
• BD Insyte Autoguard33 models · 4,465 reports · 8 recalls
• BD SafetyGlide17 models · 2,185 reports
• BD Vacutainer Eclipse Blood Collection Needle4 models · 1,880 reports
• BD Vacutainer Push Button Blood Collection Set9 models · 1,831 reports
• BD Nexiva25 models · 1,614 reports · 1 recall
• BD BACTEC MGIT Mycobacteria Growth Indicator Tubes2 models · 1,554 reports